Moreover, Ross-Innes CS et al. reported that risk stratification using two methylation markers (MYOD1, RUNX3) along with three protein biomarkers (p53, c-Myc, Aurora kinase A) was useful to avoid overdiagnosis and overtreatment in routine clinical practice for patients with BE [87]. This evidence concerns the gene MYC and Barrett esophagus.